Researchers at Washington University in St. Louis have developed an improved process for conditioning patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) using JAK inhibitors. Commonly used to treat autoimmune diseases like rheumatoid arthritis, JAK inhibitors are less toxic than chemotherapy or radiation as conditioning agents but still show efficacy in preventing graft rejection.
AlloHSCT is an effective treatment option for several diseases including acute myeloid leukemia, although patients often have difficulty tolerating the aggressive chemotherapy- or radiation-based conditioning regimens. This has led to the emergence of reduced-intensity conditioning for alloHSCT, which sacrifices some efficacy for increased tolerability in particularly vulnerable patient groups. Adding a JAK inhibitor to the conditioning protocol could reduce or eliminate the need for more aggressive agents, providing higher efficacy with lower toxicity.
Stage of Research